Le Lézard
Classified in: Health
Subjects: WOM, MRR

Menopause Market to Grow Rapidly at a CAGR of 1.2% by 2032, Predicts DelveInsight

The menopause market is anticipated to surge significantly in the coming years due to the emergence of new products in the pipeline. In addition, persistently rising cases of menopause in the forecast period will help increase the menopause treatment market. 

LAS VEGAS, Sept. 12, 2023 /PRNewswire/ -- DelveInsight's Menopause Market Insights report includes a comprehensive understanding of current treatment practices, menopause emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].


Key Takeaways from the Menopause Market Report

Discover which therapies are expected to grab the major menopause market share @ Menopause Market Report

Menopause Overview

Menopause is a natural biological process that marks the end of a woman's reproductive years. It usually occurs between the ages of 45 and 55, with an average age of around 51. This phase is characterized by a decline in the production of hormones like estrogen and progesterone, leading to the cessation of menstruation and fertility. The primary cause of menopause is the aging of the ovaries, which results in a reduced number of eggs and a decline in hormone production. However, certain medical procedures like hysterectomy, chemotherapy, and radiation therapy can induce menopause prematurely.

Menopause brings about a range of symptoms that can vary widely from woman to woman. Common menopause symptoms include hot flashes, night sweats, mood swings, irritability, fatigue, vaginal dryness, and sleep disturbances. These symptoms occur due to the hormonal fluctuations that take place during the transition to menopause. Diagnosing menopause is often based on a woman's age, medical history, and symptoms. A key factor is the absence of menstruation for 12 consecutive months, signaling the end of the reproductive period. In some cases, healthcare providers may recommend blood tests to measure hormone levels, such as follicle-stimulating hormone (FSH) and estrogen, to confirm the onset of menopause.

Menopause Epidemiology Segmentation

DelveInsight estimates that there were approximately 100 million total women in menopause in the 7MM in 2022.

For the age-specific analysis, the number of cases of menopause were distributed across various age groups, such as <40 years, 40?50 years, 51?60 years, and 61?65 years, in the 7MM. As per the analysis, the highest number of cases were estimated in the age-group 51-60 years and the lowest in <40 years with 64 million and 3.4 million cases, respectively in 2022.

The menopause market report proffers epidemiological analysis for the study period 2019?2032 in the 7MM segmented into:

Menopause Treatment Market 

The North American Menopause Society (NAMS) suggests waiting until the hot flashes become troublesome to the woman before seeking treatment. The intensity of symptoms, an assessment of treatment-related risks, and the woman's views towards menopause and drugs should all be considered before starting treatment. Duavee (bazedoxifene acetate/conjugated estrogens) is the first and only medicine that combines CE with an estrogen agonist/antagonist, commonly known as a selective estrogen receptor modulator (SERM), for the treatment of menopausal VMS. Duavee employs bazedoxifene rather than progestin to help protect the uterine lining from hyperplasia that may occur as a result of estrogen-only treatment.

Many women use non-prescription therapies to address disorders such as hot flashes, such as isoflavones, black cohosh, and progesterone-containing hormone lotions. The clinical evidence for the efficacy and long-term safety of these therapies is insufficient. Furthermore, most over-the-counter medications for hot flashes are classified as nutritional supplements and, as such, are not regulated by the US Food and Drug Administration. Prescription medications for various purposes that have demonstrated some benefit in alleviating hot flashes are available for women who have hot flashes but cannot undergo hormone therapy. Certain prescription antidepressants may reduce hot flashes in women, including those with a history of breast cancer. Others include gabapentin, clonidine, and methyldopa. The NAMS recommends that women who need relief from mild menopause-related hot flashes first consider lifestyle changes such as manipulating the environment to keep the core body temperature cool, getting regular exercise, quitting smoking, and using relaxation techniques such as paced respiration.

To know more about menopause treatment, visit @ Menopause Treatment Drugs 

Key Menopause Therapies and Companies

Learn more about the FDA-approved drugs for menopause @ Drugs for Menopause Treatment 

Menopause Market Dynamics

The menopause market dynamics are undergoing significant shifts as societal awareness of women's health and well-being continues to grow. With an aging population and increasing focus on women's empowerment, there's a heightened demand for innovative products and services addressing the physical and emotional challenges associated with menopause. This has spurred a surge in research and development, leading to the creation of a diverse range of hormone replacement therapies, herbal supplements, lifestyle apps, and personalized health plans

As more women seek effective and holistic solutions, companies are embracing a more consumer-centric approach, tailoring their offerings to individual needs and preferences. Additionally, discussions around menopause are becoming less taboo, allowing for open dialogue and information-sharing, further shaping the menopause market dynamics by fostering a supportive ecosystem for women navigating this life stage.

However, despite the potential for growth, this menopause market is not without its barriers. Stringent regulatory processes for hormonal treatments and supplements, coupled with concerns about product safety and efficacy, pose challenges for menopause market entrants. Additionally, cultural stigmas and misinformation surrounding menopause still exist in certain societies, inhibiting open discussions and the adoption of new solutions. Economic disparities and limited access to healthcare further compound these issues, preventing equal menopause market penetration. Overcoming these barriers requires a multi-faceted approach, involving education, regulatory reforms, and inclusive product development, to truly tap into the menopause market's potential.

Report Metrics


Study Period



7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]

Menopause Market CAGR

1.2 %

Menopause Market Size in 2022

USD 11 Billion

Key Menopause Companies

Viramal Limited, Simbec Research, Estetra, Mithra Pharmaceuticals, Bayer, Nerre Therapeutics Ltd., Mitsubishi Tanabe Pharma America Inc., MenoGeniX, QUE Oncology, Fervent Pharmaceuticals, and others

Key Menopause Therapies

Transdermal Estradiol Cream (VML-0203), DONESTA (E4, Estetrol), Elinzanetant (BAY3427080), MT-8554 (Elismetrep), MNGX-100 (Filgrastim/G-CSF), Q-122 (MSX-122), FP-101, and others


Scope of the Menopause Market Report

Discover more about menopause drugs in development @ Menopause Clinical Trials

Table of Contents


Menopause Market Key Insights


Menopause Market Report Introduction


Menopause Market Overview at a Glance


Menopause Market Executive Summary


Disease Background and Overview


Menopause Treatment and Management


Menopause Epidemiology and Patient Population


Patient Journey


Menopause Marketed Drugs


Menopause Emerging Drugs


Seven Major Menopause Market Analysis


Menopause Market Outlook


Potential of Current and Emerging Therapies


KOL Views


Unmet Needs


SWOT Analysis




DelveInsight Capabilities




About DelveInsight


Related Reports

Hot Flashes Pipeline

Hot Flashes Pipeline Insight ? 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key hot flashes companies, including Veru Healthcare, Fervent Pharmaceuticals, Ogeda, Bayer, Lundbeck A/S, TherapeuticsMD, MenoGeniX, Mitsubishi Tanabe Pharma, QUE Oncology, Pherin Pharmaceuticals, among others.

Hot Flashes Market

Hot Flashes Market Insight, Epidemiology, and Market Forecast ? 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key hot flashes companies, including Veru Healthcare, Fervent Pharmaceuticals, Ogeda, Bayer, Lundbeck A/S, TherapeuticsMD, MenoGeniX, Mitsubishi Tanabe Pharma, QUE Oncology, among others.

Menopause Global Market

Menopause Market Insights, Competitive Landscape, and Market Forecast ? 2028 report deliver an in-depth understanding of the disease, market trends, market drivers, market barriers, and key menopause companies including ISIDEN, Novapharm, Arkopharma, Pileje, Thermamex, ÉLERTÉ Laboratories, Serelys Pharma, Besins Healthcare, Bayer, ITALFARMACO S.p.A, Pfizer Inc, Mylan NV, Teva Pharmaceuticals, TherapeuticsMD, Inc, Novo Nordisk, Novartis, Millicent Pharma, PADAGIS LLC, Vertical Pharmaceuticals LLC, Amgen, among others.

Vasomotor Symptoms of Menopause Pipeline

Vasomotor Symptoms of Menopause Pipeline Insight ? 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key vasomotor symptoms of menopause companies, including Mithra Pharmaceuticals, Acer Therapeutics, QUE Oncology, Bayer, Endoceutics, Astellas Pharma, Mitsubishi Tanabe Pharma, MenoGenix, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur
[email protected]   

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg 


SOURCE DelveInsight Business Research, LLP

These press releases may also interest you

at 08:44
New Year's resolutions are a common way people motivate themselves to focus and regain positive momentum heading into each year. In 2023, the most popular resolutions included saving money, spending time with friends and family, and reducing things...

at 08:42
The holidays may be billed as the most wonderful time of the year, but that wonder comes at a cost. The final weeks of the year are filled with crowded schedules as individuals hop from one party and event to the next. Travel is hectic and...

at 08:42
The pharmaceutical world often focuses on specific ingredients. If an individual is in pain, they can take ibuprofen or acetaminophen. If they have digestive issues, they might take omeprazole. These highly targeted medical solutions have their...

at 08:42
The Bob Woodruff Foundation is proud to announce investments of $2.8 million in 75 organizations that work to ensure veterans, service members, and their families can lead stable and successful lives. Overall, in 2023, the Foundation provided over $9...

at 08:41
Joint health is a common concern among multiple demographics. Seniors consistently invest in ongoing care to maintain flexibility and mobility in aging bones and joints. Those who struggle with weight also wrestle with concerns about overtaxed...

at 08:40
Superoxide dismutase (SOD) is the first essential enzyme in the antioxidant pathway. It is a primary shield against oxidative stress and can help maintain health on a cellular level in multiple ways when it is taken in the correct doses. "SOD is key...

News published on and distributed by: